Vivek Subbiah: HER2 mutant NSCLC now has an oral TKI option without ILD

Vivek Subbiah shared a post by Chul Kim, on X, adding:

”Wow! HER2 mutant non-small cell lung cancer (NSCLC) now has an oral tyrosine kinase inhibitor (TKI) option without interstitial lung disease (ILD).

Nice overall response rate (ORR).

• ORR = 72.1%,
• ORR = 90.0%, among HER2 Y772_A775dup insertion.”

Quoting Chul Kim’s post:

”PL04.03 – Safety and Efficacy of BAY 2927088 in HER2-Mutant Non-Small Cell Lung Cancer (NSCLC): Expansion Cohort from the Phase I/II SOHO-01 Study:

• Overall response rate (ORR) = 72.1% (90.0% among HER2 Y772_A775dup insertion),
• Duration of response (DOR) = 8.7 months,
• Most common adverse event: Diarrhea (no reports of interstitial lung disease/pneumonitis).

Impressive results!”

Source: Vivek Subbiah/X and Chul Kim/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.

Chul Kim holds the position of Associate Professor at Georgetown University, specializing in thoracic oncology. Dr. Kim was recognized with the Norman Rales Young Investigator Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) in 2018. In 2021, he was presented with the John F. Potter, MD, Award by Georgetown Lombardi Comprehensive Cancer Center. Dr. Kim actively contributes to the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has authored more than 60 articles in reputable peer-reviewed journals.